Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial - Wikidata - wikimedia - TriplyDB

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

http://www.wikidata.org/entity/Q33997879

about

Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives Sequence of treatment in locally advanced and metastatic renal cell carcinoma A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study Immunologics and chemotherapeutics for renal cell carcinoma.Targeted treatments in advanced renal cell carcinoma: focus on axitinib.Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.Axitinib for the treatment of advanced renal cell carcinoma.Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.The circadian timing system in clinical oncology.Alternate sunitinib schedules in patients with metastatic renal cell carcinoma.Axitinib plasma pharmacokinetics and ethnic differences.A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.Axitinib in metastatic renal cell carcinoma.Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.Axitinib: a review in advanced renal cell carcinoma.Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma.Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation.Axitinib for the treatment of metastatic renal cell carcinoma.Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline.Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience.Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer.Pharmacotherapy for treating metastatic clear cell renal cell carcinoma.A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma.Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma.Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.Hypertension and VEGF (Vascular Endothelial Growth Factor) Receptor Tyrosine Kinase Inhibition: Effects on Renal Function.

P2860

Q26751341-32B7EE46-D117-4A4E-A5AD-052071CD7DB4 Q26773653-01813EF0-3718-477E-BC06-0C06AED75AC3 Q26774752-23078EB5-D734-456A-A75F-801E01100373 Q27028048-A04AD4C8-855C-4344-AB56-A0C92AEF936A Q28066747-22CDDE65-5A99-4AEC-8250-D2B98C893725 Q33419633-35B5CE4C-8EF1-4CE4-AAF8-089042CAD041 Q33633424-AB64F8FD-C697-40E8-A0C4-89ED7CBAF03A Q33823247-7D919ED7-35AF-4824-918E-C044FB58684A Q34660154-1F29B140-4AD2-4F48-9A64-1458A2DE043C Q34661185-62998377-D0DE-4FA1-A076-D5D181CF5665 Q35079536-34CA320F-E533-48D4-B335-3CE69B218E27 Q35413876-46ACA5F4-0095-481F-B105-EB16A4EB90F3 Q35562209-8DEB7E98-6613-49C8-A487-3ADA2EFED1CC Q35758408-D80B75D2-96AA-4063-B3CC-D39FBD7D9FA6 Q36051199-35C29618-8D12-4814-96FE-8A1293BA6C6A Q37387563-972CEC56-7A37-4667-A5B0-E1615FFFD1EC Q38170397-0FEB13E0-075D-4454-A4C6-84853DC1E265 Q38190857-B3033C36-FF5F-4A66-AEFC-C18A9152B60B Q38196855-52107F1D-65B3-476E-A75B-30A0DC715F38 Q38201503-A265EA4F-B38F-4D14-8425-7056804BBE08 Q38219193-6471B416-81AD-4859-ABF5-C254105F52C2 Q38335105-D6482790-7A91-46C3-82AA-7D9716A1D4C5 Q38348548-FC4FCFB2-A646-431D-913A-6D9C70FCEE6A Q38378485-CD1A4891-A3DB-4A1F-B422-D21E2471FA39 Q38439661-26447B27-16C0-4401-965A-E7985BFAE238 Q38514440-101AE442-BFD3-4689-BDF5-3766D8F54123 Q38612808-518D7E18-4BDA-4F5D-95D0-2396575D7AED Q38628043-37E10D0A-3925-4B6B-BA5D-8119C2FEBA0C Q38655156-E83D2FD1-40A3-4A90-B771-CD5ED77A8B5F Q38657787-277FC220-8D9C-4A13-8182-BC3472A2DAFD Q38673512-C81FAB04-D3B2-45E9-BEFC-1F7E273272BE Q38697227-87EF3C8A-D363-4E89-812D-66CD56C0AA77 Q38836780-C05EE542-4D74-4660-95AD-6D7017C7520E Q38975599-0312B75E-C8A9-4A15-B47F-EA9B6335FEE4 Q39044249-8E3BEFBE-3B95-4A89-94E6-58ACE660D1EC Q39095194-DF71B085-64E1-4A9B-8A84-D6E200727605 Q39100001-EE90BD34-E52D-4A15-8CBF-FE96447A4403 Q39219788-A7182B45-B91C-47C9-97E3-E557C42D2734 Q39429946-DCC65656-880F-41B0-BEC5-7A9BFBC523BD Q40109938-FF3E619D-F1CA-4F30-A613-C7D23D949D88

P2860

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

http://www.wikidata.org/entity/Q33997879

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Axitinib with or without dose ...... sed double-blind phase 2 trial

@ast

Axitinib with or without dose ...... sed double-blind phase 2 trial

@en

type

label

Axitinib with or without dose ...... sed double-blind phase 2 trial

@ast

Axitinib with or without dose ...... sed double-blind phase 2 trial

@en

prefLabel

Axitinib with or without dose ...... sed double-blind phase 2 trial

@ast

Axitinib with or without dose ...... sed double-blind phase 2 trial

@en

P1433

Q33997879-53BA971F-FD77-4D36-9FF5-DADB229A6AF6

P1476

Q33997879-7C9A3754-4E2C-4FD7-9396-8E0C98CF6949

P2093

Q33997879-05801EE5-0DED-41C2-99D9-5872F271F871

Q33997879-0E390CD4-1EA5-417E-990A-D3B80E711D33

Q33997879-11485F5A-322C-4F2A-A3E7-CA07603620E3

Q33997879-2D4AD062-EF28-471E-B6CB-49E2EC596B2C

Q33997879-41922B9F-0315-44E9-9D11-8C108D388B08

Q33997879-68F4BBD0-CD32-4435-B5FE-15E6454F3340

Q33997879-989A11AA-93B6-4D59-A94B-AACF105F8482

Q33997879-B487F413-030E-4ABA-9FFF-96DFA05B8ECF

Q33997879-BA6D314D-EBD1-4EE1-BD1B-BF7545B7C38F

Q33997879-BD2668EC-3FB7-479B-99A7-9FDFF04E4DED

P2860

Q33997879-00A6E42B-2E4E-40FF-BE52-AB0C0180C18E

Q33997879-12408538-21C6-44EC-A773-A50D9FC7BC7F

Q33997879-14471095-29DF-499D-BF4E-4ED1CDC7002A

Q33997879-202B65B7-54CA-4321-9920-BF045ABAAB10

Q33997879-2EF873BB-EA01-43A5-84AF-EDBE7AFE0A24

Q33997879-304BD95C-00D3-4A08-8810-79A42D41EBC3

Q33997879-31EB79FD-6D36-4000-9D21-1DF7B6EEDC99

Q33997879-32AAE929-6769-4B1F-BEE9-2D83913CACE8

Q33997879-45429E65-506B-4CCB-8864-8B6C2F4ED781

Q33997879-554D9C53-6A9D-4BC2-A317-557F49357131

P304

Q33997879-28081711-8D49-4ECA-8442-84616CDDD7B5

P31

Q33997879-AC438E02-1F80-43D7-9972-7F0444A992E2

P356

Q33997879-72B313B6-5A91-461C-9E35-036F30D7045F

P433

Q33997879-009E2453-97E7-4FE6-9700-C2533F6FA5CB

P478

Q33997879-09E61F06-D1FE-400C-9FB7-7BE480EFBB54

P577

Q33997879-0AE7BBBC-512C-45ED-8B18-A8C0B60731A5

P698

Q33997879-B11FA7C7-80C1-4025-A6F9-30C456D3B3BB

P921

Q33997879-CC679AE9-DADE-4582-B8FD-CC19EE360021

P932

Q33997879-8629A592-18F1-44EB-83CC-EBDF2485C68C

P356

S1470-2045(13)70464-9

P1433

The Lancet Oncology

P1476

Axitinib with or without dose ...... sed double-blind phase 2 trial

@en

P2093

Angel H Bair

http://www.w3.org/2001/XMLSchema#string

Bohuslav Melichar

http://www.w3.org/2001/XMLSchema#string

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Dmitri Pavlov

http://www.w3.org/2001/XMLSchema#string

Eric Jonasch

http://www.w3.org/2001/XMLSchema#string

Glen I Andrews

http://www.w3.org/2001/XMLSchema#string

José A Arranz

http://www.w3.org/2001/XMLSchema#string

Mayer N Fishman

http://www.w3.org/2001/XMLSchema#string

Sinil Kim

http://www.w3.org/2001/XMLSchema#string

Takeshi Ueda

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

P304

1233-1242

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(13)70464-9

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24140184

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

4120767

http://www.w3.org/2001/XMLSchema#string